12 results match your criteria: "Children Hospital of La Timone[Affiliation]"
Environ Res
January 2024
Inserm UMR1153, Epidemiology of Childhood and Adolescent Cancers (EPICEA) team, Université Paris Cité and Université Sorbonne Paris Nord, Inserm, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), Paris, France; French National Registry of Childhood Cancers, RNHE, Hôpital Paul Brousse, Groupe Hospitalier Universitaire Paris-Sud, AP-HP, Villejuif, and RNTSE, CHRU de Nancy, Vandœuvre-lès-Nancy, France. Electronic address:
Background: Exposure to pesticides has been suggested as a potential risk factor for childhood embryonal tumour. The existing literature has mainly focused on parental occupational exposure and domestic use of pesticides, and is very limited for residential exposures to agricultural pesticides. The study aimed to test the hypothesis of an increased risk of embryonal tumour in children living close to viticultural plots, likely to be subject to frequent pesticide applications.
View Article and Find Full Text PDFJ Clin Med
February 2023
Department of Pediatric Immunology, Hematology and Oncology, Children Hospital of La Timone, Assistance Publique Hôpitaux de Marseille, 13005 Marseille, France.
Background: Relapses in pediatric high-risk brain tumors remain unmet medical needs. Over the last 15 years, metronomic chemotherapy has gradually emerged as an alternative therapeutic approach.
Patients And Methods: This is a national retrospective study of patients with relapsing pediatric brain tumors treated according to the MEMMAT or MEMMAT-like regimen from 2010 to 2022.
Cancer Med
April 2023
Inserm, UMR 1153 Centre of Research in Epidemiology and StatisticS (CRESS), Epidemiology of childhood and adolescent cancers team (EPICEA), Villejuif, France.
Few studies have investigated the seasonal patterns of embryonal tumours. Based on data from the French National Registry of Childhood Cancers, the present study aimed to investigate seasonal variations in embryonal tumour incidence rates by month of birth and by month of diagnosis. The study included 6635 primary embryonal tumour cases diagnosed before the age of 15 years over the period 2000-2015 in mainland France.
View Article and Find Full Text PDFLancet Child Adolesc Health
November 2021
Arthur and Sonia Labatt Brain Tumor Research Centre, Hospital for Sick Children, Toronto, ON, Canada; Division of Haematology/Oncology, Department of Pediatrics, Hospital for Sick Children, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada. Electronic address:
Background: Embryonal tumours with multi-layered rosettes (ETMRs) are a newly recognised, rare paediatric brain tumour with alterations of the C19MC microRNA locus. Due to varied diagnostic practices and scarce clinical data, disease features and determinants of outcomes for these tumours are poorly defined. We did an integrated clinicopathological and molecular analysis of primary ETMRs to define clinical phenotypes, and to identify prognostic factors of survival and key treatment modalities for this orphan disease.
View Article and Find Full Text PDFEur J Cancer
September 2021
Department of Pediatric Immunology, Hematology and Oncology, Children Hospital of La Timone, AP-HM, Marseille, France; SMARTc Unit, Centre de Recherche en Cancérologie de Marseille, Inserm U1068, Aix Marseille Univ, Marseille France. Electronic address:
Background And Aims: COVID-19 infection in paediatric patients with cancer is severe or critical in 20% of the patients. It can therefore directly affect paediatric patients with cancer and/or their care. We aimed at evaluating the safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults (AYA) with solid tumour.
View Article and Find Full Text PDFLancet
July 2021
Metronomic Global Health Initiative, Children Hospital of La Timone, AP-HM, Aix Marseille Université, Marseille, France.
Childs Nerv Syst
February 2016
Department of Pediatric Hematology-Oncology, APHM, La Timone Hospital, 264 rue Saint-Pierre, 13005, Marseille, France.
Purposes: The purpose of this study was to retrospectively study embryonal tumors with multilayered rosettes (ETMR), a rare new entity that gathers ETAN-TR (embryonal tumor with abundant neuropil and true rosettes), ependymoblastomas, and medulloepitheliomas, in order to improve their descriptions and try to better define therapeutic modalities.
Methods: Patients with ETMR, ETAN-TR, ependymoblastoma, and medulloepithelioma treated in SFCE centres (Société Française de lutte contre les Cancers et les leucémies de l'Enfant et de l'adolescent) since 2000 were collected. Data were retrieved from clinical charts.
J Pediatr Hematol Oncol
November 2013
*Department of Pediatric Hemato-Oncology, University Hospital Marrakech, Morocco Departments of †Pediatric Hemato-Oncology ‡Radiotherapy, Children Hospital of La Timone, AP-HM §Metronomics Global Health Initiative Marseille, France.
Am J Med Genet A
March 2007
Multidisciplinary Paediatric Department, Children Hospital of "La Timone", Boulevard Jean Moulin, Marseille Cedex, France.
Tricho-hepato-enteric syndrome and syndromic diarrhea are quite rare conditions with only 15 patients described to date. Both include severe diarrhea requiring total parenteral nutrition, facial dysmorphism, immunity defect, and hair abnormalities (mostly trichorrhexis nodosa). A definite clear clinical description of the two syndromes is lacking; the outcome is also poorly known.
View Article and Find Full Text PDFAnticancer Drugs
March 2007
Department of Pediatric Oncology, Children Hospital of La Timone, Marseille, France.
The myelotoxicity of most chemotherapeutic regimens used to treat children and adolescents with cancer require the use of daily subcutaneous administration of hematological growth factors (mainly granulocyte colony-stimulating factor). Recently, pegfilgrastim (Neulasta), a product with a long half-life, resulting in once-per-cycle dosage, was introduced to prevent neutropenia in adults, and provided safety and efficacy similar to that provided by daily injection of filgrastim. To evaluate retrospectively the use of pegfilgrastim in children with cancer, we conducted a single-center retrospective study evaluating the use of pegfilgrastim in patients over 40 kg, who received chemotherapy for cancer from September 2003 to December 2005.
View Article and Find Full Text PDFAnticancer Drugs
November 2006
Department of Pharmacy, Children Hospital of la Timone, Marseille, France.
We report the case of an 11-year-old girl with a recurrent progressive locally advanced abdominal mesothelioma. First, there was an incomplete surgical resection without any complementary chemotherapy, followed by a slow progression of the disease. Three years later, after two macroscopically complete surgical resections of peritoneal and ovarian tumors, she failed to respond to treatment with gemcitabin-carboplatin and gemcitabin-cisplatin, and developed splenic tumors and large multicystic hepatic tumors.
View Article and Find Full Text PDFMed Hypotheses
February 2005
Pediatric Oncology Department, Children Hospital of "La Timone", Bd Jean Moulin, 13885 Marseille Cedex 5, France.
Cyclosporine A is the most commonly used immunosuppressive agent during organ transplantation. One of the most feared adverse effects of cyclosporine A is the appearance of de novo cancers. The mechanisms that lead to the genesis of such cancers are thought to be only related to a side effect of cyclosporine A: a depressed immune system.
View Article and Find Full Text PDF